Role of Post-Treatment $^{18}$F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients Receiving Definitive Chemoradiation for Locally Advanced Head and Neck Squamous Cell Carcinomas

Jae-Joon Kim$^1$, Sang-Bo Oh$^1$, Ki Sun Jung$^1$, Kwonoh Park$^1$, Seong-Jang Kim$^2$, Yongkan Ki$^3$, Jin-Choon Lee$^4$, and So Yeon Oh$^1$

$^1$Oncology and Hematology Clinic, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan; and Departments of $^2$Nuclear Medicine, $^3$Radiation Oncology, and $^4$Otolaryngology-Head and Neck Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea

Background and Objectives $^{18}$F-fluorodeoxyglucose PET/CT scans can be a useful method to detect recurrence. However, its role in locally advanced head and neck squamous cell carcinomas (HNSCCs) patients after definitive chemoradiotherapy (CRT) has not yet been determined. The current study was performed to identify the role of therapeutic response evaluation using PET/CT after definitive CRT.

Subjects and Method We conducted a retrospective review of patients with locally advanced HNSCCs, and who have undergone definitive CRT from 2009 to 2017 at a single institution. The patients were divided into two groups according to their responses to the treatment (metabolic complete remission [mCR] group or non-mCR group), assessed by PET/CT scans after definitive CRT.

Results Twenty-eight patients were consecutively enrolled. The most common primary site of cancer was the oropharynx, followed by the oral cavity, hypopharynx, and nasal cavity. The therapeutic response assessed by PET/CT scans was mCR in 14 patients. The median progression-free survival (PFS) was not reached in the mCR group but was 13.3 months for the non-mCR group ($p=0.001$). The median overall survival was significantly longer for the mCR group (52.5 months) than for the non-mCR group (15.2 months, $p=0.002$). A multivariate analysis showed PET/CT response and high-sensitivity C-reactive protein (hsCRP) as independent prognostic factors for PFS (mCR: $p=0.027$; hsCRP: $p=0.042$) and for the overall survival (mCR: $p=0.006$; hsCRP: $p=0.020$).

Conclusion PET/CT scans after definitive CRT predicted the prognosis in patients with locally advanced HNSCCs. CRP was a prognostic factor affecting the outcomes of treatments.

Keywords Chemoradiotherapy; Head and neck squamous cell carcinoma; Positron-emission tomography; Prognostic factor; Response evaluation criteria in solid tumors.

Received July 5, 2022
Revised September 17, 2022
Accepted October 4, 2022
Address for correspondence
So Yeon Oh, MD, PhD
Oncology and Hematology Clinic, Department of Internal Medicine, Pusan National University Yangsan Hospital, 20 Geumo-ro, Mulgeum-eup, Yangsan 50612, Korea
Tel +82-55-360-2369
Fax +82-55-360-2150
E-mail manic2db@gmail.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Head and neck squamous cell carcinoma (HNSCC) includes cancers of the oral cavity, oropharynx, hypopharynx, and larynx. Globally, 800000 people are diagnosed with HNSCC annually.1-3 Locoregional HNSCC is treated with curative intent using multimodal treatments such as surgery, radiation treatment, chemotherapy, or their combinations.4 In locally advanced HNSCC patients who are not candidates for surgery, combined chemoradiotherapy (CRT) is the mainstay of treatment.5 However, despite multimodal treatment, over 50% of patients with locally advanced HNSCC experience progression or recurrence within 3 years of treatment.6 Providing additional treatment to patients who did not achieve a complete response (CR) after CRT may therefore be an effective therapeutic approach. Thus, accurate response evaluation after CRT is very important. However, due to radiation-induced tissue reactions, such as fibrosis, the response evaluation after CRT is not as simple as response assessment after chemotherapy.7 Moreover, changes in tumor vascularity or metabolic activity cannot be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, which is considered the gold standard for assessing the tumor response after CRT. Studies on complementary modalities, such as CT perfusion, MRI, and PET/CT, are being conducted to improve the accuracy of post-CRT response evaluations.8-11 PET/CT is a nuclear medicine modality that combines PET and CT. Imaging with 18F-fluorodeoxyglucose (FDG)-PET/CT can evaluate tumors based on biochemical changes and therefore plays an important diagnostic role in oncologic clinical practice.12 PET/CT after definitive CRT is considered a useful tool for earlier detection of recurrence during routine surveillance.13,14 PET may also provide a prognostic marker for predicting treatment responses and survival outcomes in locally advanced HNSCC after treatment.14,15

In previous studies, PET/CT after CRT showed a prognostic value in assessing overall survival (OS) and progression-free survival (PFS), and was useful in predicting immediate therapeutic failures.16 However, there is uncertainty about the role of PET/CT after CRT. We therefore determined the efficacy and the role of PET/CT in locally advanced HNSCC patients who received CRT.

Subjects and Methods

Patients and data collection

Patients who were diagnosed with HNSCC and treated with definitive CRT were retrospectively evaluated. Locally advanced HNSCC was defined as HNSCC which cannot be easily removed by surgery including advanced T stage (T3 or greater) or advanced neck lymph node (N2 or greater) without distant metastasis. Patients who were diagnosed with squamous cell carcinoma in cervical lymph nodes from unknown primary sites but presumed to be of head and neck origin were also included. Among patients who received definitive CRT, those who were evaluated with PET/CT scans before and 12 weeks after CRT were evaluated. Clinical factors and treatment outcomes were obtained from medical records. This study was approved by the Institutional Review Boards of Pusan National University Yangsan Hospital (IRB No. 05-2021-186).

Response evaluation

Patients were evaluated for disease status by PET/CT before and 12 weeks after CRT. Response interpretation was evaluated according to Deauville criteria (Table 1). Complete metabolic remission was defined as Deauville scores of 1, 2, or 3 and no or minimal FDG uptake (less than the mediastinal blood pool) or low-grade uptake (less than in the liver). Non-CR was defined as moderate focal uptake (more than in the liver; Deauville score of 4) or intense focal uptake (Deauville score of 5). In most patients, the maximum standardized uptake value (mSUV) was also recorded. Among the patients with a Deauville score of 3, those with a mSUV ≥3.5 were categorized as non-metabolic complete remission (mCR) in this study.

Statistical analysis

PFS was defined as the time from the start of treatment un-
Role of PET/CT Scans After CRT in HNSCC

Kim JJ, et al.

months. In all patients, the median PFS was 19.8 (95% confidence interval [CI]: 10.7–28.9) months and the median OS was 34.8 (95% CI: 26.7–42.8) months. The median PFSs in the mCR was not reached and median PFS in the non-mCR groups was 13.3 (95% CI: 6.0–20.6) months. The median OS in the mCR group and non-mCR group were 52.5 (95% CI: 0–144.4) and 15.2 (95% CI: 10.9–19.5) months, respectively. The PFS and OS were longer in the mCR group and had a better statistical significance than the non-mCR group (Table 4 and Fig. 1).

Univariate and multivariate analyses

In the univariate analyses for PFS, the following were not significant factors: age, sex, Eastern Cooperative Oncology Group Performance Status, cancer stage, smoking history, tumor differentiation, weight loss during CRT, neutrophil to lymphocyte ratio (NLR), and radiation dose. Diabetes ($p=0.034$), high-sensitivity C-reactive protein (hsCRP) ($\leq 1.0$ vs. $>1.0$, $p=0.017$), and PET/CT response were significant factors for PFS. In multivariate analysis for PFS, hsCRP mea-

### Results

#### Patient characteristics

Between November 2009 and March 2017, 28 patients were consecutively enrolled in current study. Table 2 shows the patient characteristics. Fourteen patients were assessed as mCR by PET scans 12 weeks after CRT, and 14 patients were evaluated as non-mCR. The majority of patients were stage IV without distant metastases. Four patients underwent induction chemotherapy before CRT and most patients received CRT with a cisplatin-based regimen (Table 2).

#### Response and survival

When assessing disease status after CRT, 11 patients achieved mCR and 17 patients did not achieve mCR. Patients of larynx and unknown origin were all mCR and 45.5% of oropharyngeal origin patients achieved mCR (Table 3). In 11 patients who achieved mCR, CT or MRI results did not show CR with PET/CT in 4 patients (PR in 2 patients, SD in 1 patient). In non-mCR group, 12 patients showed PR and 5 patients showed SD in CT or MRI. The median follow-up was 34.2 (2.6–140.5) months. In all patients, the median PFS was 19.8 (95% confidence interval [CI]: 10.7–28.9) months and the median OS was 34.8 (95% CI: 26.7–42.8) months. The median PFSs in the mCR was not reached and median PFS in the non-mCR groups was 13.3 (95% CI: 6.0–20.6) months. The median OS in the mCR group and non-mCR group were 52.5 (95% CI: 0–144.4) and 15.2 (95% CI: 10.9–19.5) months, respectively. The PFS and OS were longer in the mCR group and had a better statistical significance than the non-mCR group (Table 4 and Fig. 1).

#### Table 2. Patient characteristics (n=28)

| Characteristics Value |
|-----------------------|
| Age (yr) 61.0 (48–82) |
| Sex Male 22 (78.6) Female 6 (21.4) |
| ECOG PS 0, 1 21 (75.0) Other 7 (25.0) |
| Primary origin Oropharynx 11 (39.3) Oral cavity 7 (25.0) Hypopharynx 5 (17.9) Nasal cavity 3 (10.7) Larynx 1 (3.6) Others 1 (3.6) |
| Stage I 0 II 1 (3.6) III 1 (3.6) IVA 22 (78.6) IVB 4 (14.3) |
| T, N, M staging T1/T2/T3/T4 2 (7.1)/4 (14.3)/4 (14.3)/17 (60.7) NO/N1/N2/N3 5 (17.9)/8 (28.6)/12 (42.9)/3 (10.7) MO/M1 28 (100)/0 |
| Induction chemotherapy Yes 4 (14.3) No 24 (85.7) |
| Chemotherapy regimen (induction) Docetaxel/cisplatin 3 Fluorouracil/cisplatin 1 |
| Chemotherapy regimen Cisplatin 14 (50.0) Cetuximab 2 (7.1) Docetaxel/cisplatin 4 (14.3) Paclitaxel/cisplatin 8 (28.6) |
| Radiation dose $\geq 60$ Gy 20 (71.4) $< 60$ Gy 8 (28.6) |
| Smoking history Yes 8 (28.6) No 20 (71.4) |

Data are presented as median (range) or n (%). ECOG, Eastern Cooperative Oncology Group; PS, performance status; CRT, chemoradiotherapy

www.kjorl.org 699
sured before treatment \( (p=0.042) \) and response by PET/CT after CRT \( (p=0.027) \) were independent prognostic factors (Table 5). In univariate analyses for OS, hsCRP, NLR, and PET/CT responses were significant factors. In multivariate analysis, hsCRP \( (p=0.020) \) and PET/CT responses \( (p=0.006) \) were independent prognostic factors for OS, similar to the results for PFS.

**Discussion**

In patients with locally advanced HNSCC, multimodal treatment, including surgery, radiation therapy, and chemotherapy, is the most important treatment strategy. When surgery is not possible, definitive CRT is the standard treatment. For several disease sites, such as the nasopharynx or p16-positive oropharynx, CRT has replaced surgery and has been established as a standard treatment modality for decades.\(^{17-19}\) Despite multimodality treatment, over 50% of locally advanced HNSCC patients who received treatments unfortunately experience progression or recurrence within 3 years.\(^{5,14,20}\) It is therefore important to classify and evaluate patients with a high risk of progression after CRT. Various factors including initial tumor stage, primary tumor location, HPV status, and smoking history can be prognostic factors for progression or recurrence.\(^{21}\)

In addition, other predictive markers that may help for surveillance are being widely investigated.\(^{9,22-25}\) Morphological assessment of the involved lesion is the standard method for tumor response evaluation. The original RECIST criteria and the revised version (v.1.1) have been widely used to assess the treatment responses of solid tumors.\(^{26,27}\) RECIST can be easily used because it is based on the longest diameter of the measurable lesion, but it can also be a disadvantage when size is a criterion. Due to reactive changes, such as inflammatory reactions and fibrosis, after CRT, morphological evaluation has limitations in evaluating residual cancers. To overcome this disadvantage of morphological imaging, functional imaging methods have been extensively investigated.\(^{8-10,28,29}\) Recently, morphological and functional evaluations have been shown to complement each other, so evaluating both the morphological and functional status of tumors has been accepted as the optimal evaluation method for treatment decisions.\(^{20,29}\)

PET/CT is a representative functional imaging modality that has been to evaluate the metabolic activities of tumors in patients with malignancies. PET/CT provides sequential images from both PET and CT scans, which can show metabolic activity correlated with anatomical location. In locally advanced

---

**Table 3. Response according to primary origin**

| Primary origin | mCR (%) | Non-mCR (%) |
|----------------|---------|-------------|
| Oropharynx     | 5 (45.5)| 6 (54.5)    |
| Oral cavity    | 1 (11.1)| 6 (88.9)    |
| Hypopharynx    | 2 (40.0)| 3 (60.0)    |
| Nasal cavity   | 1 (33.3)| 2 (66.7)    |
| Larynx         | 1 (100) | 0           |
| Others         | 1 (100) | 0           |

**Table 4. PFS and OS according to PET/CT responses after definitive chemoradiotherapy**

|          | mCR months (95% CI) | Non-mCR months (95% CI) | \( p \) |
|----------|---------------------|-------------------------|--------|
| PFS      | NR*                 | 13.3 (6.0–20.6)         | 0.001  |
| OS       | 52.5 (0–144.4)      | 15.2 (10.9–19.5)        | 0.002  |

*not reached because the event occurred in less than half of cases. PFS, progression-free survival; OS, overall survival; mCR, metabolic complete remission; CI, confidence interval

---

**Fig. 1.** Kaplan-Meier survival analysis of PFS (A) and OS (B) according to the PET/CT response, and mCR versus non-mCR. Both PFS and OS were significantly longer in patients with a mCR response using post-treatment PET/CT \( (p=0.001 \) for PFS, \( p=0.002 \) for OS; log-rank test). PFS, progression-free survival; OS, overall survival; mCR, metabolic complete remission.
Table 5. Univariate and multivariate analysis of PFS and OS (n=28)

|                  | PFS           | p value | OS            | p value |
|------------------|---------------|---------|---------------|---------|
|                  | Median months (95% CI) |          | Median (95% CI) (months) |          |
| **Univariate analysis** |               |         |               |         |
| Age (years)      |               |         |               |         |
| < 65 (n=17)     | 22.4 (10.8–34.0) | 0.562   | 36.5 (29.3–43.8) | 0.232   |
| ≥ 65 (n=11)     | 14.5 (6.5–28.5)  | 0.141   | 31.8 (12.8–50.8) | 0.556   |
| Sex              |               |         |               |         |
| M (n=22)         | 16.2 (8.7–23.7) | 0.512   | 33.1 (17.8–48.4) | 0.996   |
| F (n=6)          | NA*           |         | 38.0 (21.7–54.3) |         |
| ECOG PS          |               |         |               |         |
| 0, 1 (n=21)     | 25.4 (13.4–37.5) | 0.034   | 38.0 (15.7–60.3) | 0.084   |
| Other (n=7)      | 14.5 (6.3–22.7) |         | 33.1 (29.8–36.4) |         |
| Stage            |               |         |               |         |
| II–IV A (n=24)  | 22.4 (12.1–32.7) | 0.092   | 36.5 (30.0–43.0) | 0.079   |
| IVB (n=4)       | 10.1 (8.6–11.6)  |         | 15.2 (0–32.6)    |         |
| Smoking history  |               |         |               |         |
| Ever (n=8)      | 19.8 (7.9–31.7)  | 0.825   | 34.8 (13.6–56.0) | 0.897   |
| Never (n=20)    | 14.5 (0–33.4)   |         | 33.1 (22.8–43.4) |         |
| Diabetes         |               |         |               |         |
| No (n=23)       | 25.4 (0–51.1)   | 0.034   | 38.0 (30.2–45.8) | 0.084   |
| Yes (n=5)       | 13.3 (6.43–20.2) |         | 15.2 (3.5–26.9) |         |
| Tumor differentiation |           |         |               |         |
| Well differentiated (n=3) | NA | 0.885   | 38.5 (37.7–39.3) | 0.743   |
| Other (n=3) | 14.5 (2.4–26.6) |         | 33.1 (0–80.8)    |         |
| Not available (n=18) | - |         |               |         |
| Weight loss during CRT |            | 0.654   | 0.400         |         |
| < 4.9 kg (n=13) | 22.4 (11.6–33.2) | 0.017   | 33.1 (15.7–50.5) | 0.004   |
| ≥ 4.9 kg (n=14) | 19.8 (0–42.0)   |         | 36.5 (25–48.1)  |         |
| Unknown (n=1)   | -             |         |               |         |
| hsCRP            |               |         |               |         |
| < 1.0 (n=20)    | 38.5 (NA)      | 0.052   | 38.1 (37.0–39.2) | 0.034   |
| ≥ 1.0 (n=6)     | 13.3 (5.3–21.3) |         | 15.2 (2.8–59.5) |         |
| Unknown (n=2)   | -             |         |               |         |
| NLR              |               |         |               |         |
| < 2.5 (n=18)    | 22.4 (0–59.0)  | 0.052   | 36.5 (28.8–44.2) | 0.034   |
| ≥ 2.5 (n=10)    | 10.5 (8.6–12.4) |         | 31.8 (4.1–59.5) |         |
| Radiation dose  |               |         |               |         |
| < 60 Gy (n=8)   | 16.2 (2.4–30.0) | 0.544   | 36.5 (12.0–61.0) | 0.995   |
| ≥ 60 Gy (n=20)  | 19.8 (10.5–29.1) |         | 31.8 (13.0–50.6) |         |
| PET/CT response |               |         |               |         |
| mCR (n=14)      | NA            | 0.001   | 52.5 (0–144.4) | 0.002   |
| Non-mCR (n=14)  | 13.3 (6.0–20.6) |         | 15.2 (10.9–19.5) |         |
|                 | Exp (B) (95% CI) |         | Exp (B) (95% CI) |         |
| Multivariate analysis* |          |         |               |         |
| Diabetes        |               |         |               |         |
| No (n=23)       | 1.458 (0.423–5.033) | 0.551   |               |         |
| Yes (n=5)       |               |         |               |         |
| hsCRP           |               |         |               |         |
| < 1.0 (n=20)    | 3.146 (1.042–9.499) | 0.042   | 3.853 (1.233–12.043) | 0.020   |
| ≥ 1.0 (n=6)     |               |         |               |         |
| Unknown (n=2)   |               |         |               |         |
already been considered inappropriate as a criterion for judging metabolic complete remission. Status; CRT, chemoradiotherapy; hsCRP, high-sensitivity C-reactive protein; NLR, neutrophil to lymphocyte ratio; mCR, metabolic complete remission.

Deauville score, but for the indeterminate score (score 3), we additionally used mSUV for more accurate statistical analyses. In the present study, we used the Deauville score, but for the indeterminate score (score 3), we additionally used mSUV for more accurate statistical analyses. We then investigated the prognostic role of PET/CT in patients with locally advanced HNSCCs who received CRT for response evaluation and prognoses.

Many criteria have been investigated in the interpretation of PET/CT images. The SUV number for several years has already been considered inappropriate as a criterion for judging residual disease after CRT. Since the 2010s, four popular semi-quantitative evaluation criteria have been reported and validated. In a recent comparative study, four criteria showed similar diagnostic performance characteristics. Thus, any one criterion has not yet become the gold standard for PET/CT interpretation. In the present study, we used the Deauville score, but for the indeterminate score (score 3), we additionally used mSUV for more accurate statistical analyses. We then investigated the prognostic role of PET/CT in patients with locally advanced HNSCCs who received CRT. PET/CT was conducted before and approximately 12 weeks after CRT. Patients with mCR after CRT showed significantly longer PFS, and the OS was also significantly found to be longer in patients with mCR after CRT. The median OSs in patients with mCR and non-mCR were 52.5 months and 15.2 months, respectively. Using univariate and multivariate analyses, the PET/CT response of mCR after CRT was an independent prognostic factor for PFS (hazard ratio [HR]: 0.255, 95% CI: 0.076–0.854) and OS (HR: 0.249, 95% CI: 0.092–0.678). In addition, the hsCRP level before CRT was another significant prognostic factor for PFS and OS. This might be because high level of hsCRP may reflect initial high tumor burden. The results of our study were consistent with that of previous studies, which showed that PET/CT was helpful in predicting the prognosis after CRT.

Current study had several limitations due to its retrospective design and small sample size. The primary tumor site and chemotherapy regimen during CRT were heterogeneous. The number of patients was small in current study. By using an extended follow-up period, we overcame the disadvantage of small sample size and showed a statistically significant difference between the mCR and non-mCR groups. The results of this study were obtained from clinical practices, so it is meaningful that PET/CT results, which is widely used in clinics, provided a prognostic marker after CRT. However, further prospective large-scale studies will be needed to confirm the results.

In conclusion, PET/CT scans predicted the outcomes in locally advanced HNSCCs patients who received definitive CRT, and hsCRP was also a prognostic factor for treatment outcomes.

Acknowledgments
None

Author Contribution
Conceptualization: Jae-Joon Kim, So Yeon Oh. Data curation: Sang-Bo Oh, Ki Sun Jung, Kwonoh Park. Formal analysis: Seong-Jang Kim, Yongkan Ki, Jin-Choon Lee. Writing—original draft: Jae-Joon Kim, So Yeon Oh. Writing—review & editing: all authors.

ORCID
So Yeon Oh https://orcid.org/0000-0002-2562-9257
Jae-Joon Kim https://orcid.org/0000-0003-1226-2537

REFERENCES
1) Kawakita D, Oze I, Iwasaki S, Matsuda T, Matsu K, Ito H. Trends in the incidence of head and neck cancer by subsite between 1993 and 2015 in Japan. Cancer Med 2022;11(6):1553-60.
2) Burtness B, Harrington KJ, Greil R, Soulères D, Tahara M, de Castro G Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic
squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915-28.

3) Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 1998;16(4):1310-7.

4) Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94–01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22(1):69-76.

5) Licitra L, Felip E. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:S121-2.

6) Blanchard P, Baujat B, Holostenco V, Bourreddjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother Oncol 2011;100(1):33-40.

7) Straub JM, New J, Hamilton CD, Lominska C, Shnayder Y, Thomas SM. Radiation-induced fibrosis: Mechanisms and implications for therapy. J Cancer Res Clin Oncol 2015;141(11):1985-94.

8) Rana L, Sharma S, Sood S, Singh B, Gupta MK, Minhas RS, et al. Volumetric CT perfusion assessment of treatment response in head and neck squamous cell carcinoma: Comparison of CT perfusion parameters before and after chemoradiation therapy. Eur J Radiol Open 2015;2:46-54.

9) de Bree R, Wolf GT, de Keizer B, Nixon JJ, Hartl DM, Forastiere AA, et al. Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond. Head Neck 2017;39(11):2329-49.

10) Chawla S, Kim S, Dougherty L, Wang S, Loewner LA, Quon H, et al. Pretreatment diffusion-weighted and dynamic contrast-enhanced MRI for prediction of local treatment response in squamous cell carcinomas of the head and neck. AJR Am J Roentgenol 2013;200(1):35-43.

11) Goel R, Moore W, Sumer B, Khan S, Sher D, Subramanian RM. Clinical practice in PET/CT for the management of head and neck squamous cell cancer. AJR Am J Roentgenol 2017;209(2):293-303.

12) Farrell MD, Pryma DA, Mankoff DA. PET/CT imaging in cancer: Current applications and future directions. Cancer 2014;120(22):3433-45.

13) Lee JC, Kim JS, Lee JH, Nam SY, Choi SH, Lee SW, et al. F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma. Oral Oncol 2007;43(7):868-92.

14) Kim G, Kim YS, Han EJ, Yoo IR, Song JH, Lee SN, et al. FDG-PET/CT as prognostic factor and surveillance tool for postoperative radiation recurrence in locally advanced head and neck cancer. Radiat Oncol J 2011;29(4):243-51.

15) Paidpally V, Chirindel A, Lam S, Agrawal N, Quon H, Subramanian RM. FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med 2012;4(6):633-47.

16) Kim R, Ock CY, Keam B, Kim TM, Kim JH, Paeng JC, et al. Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: A retrospective study. BMC Cancer 2016;16:116.

17) Pigno JP, Bourhis J, Domengue C, Desnèl L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 2000;355(9208):949-55.

18) Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349(22):2091-8.

19) Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009;101(3):142-52.

20) Johnson DE, Burtness B, Leemans CR, Lui VYW, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020;6(1):92.

21) Brana I, Siu LL. Locally advanced head and neck squamous cell cancer: Treatment choice based on risk factors and optimizing drug prescription. Ann Oncol 2012;23 Suppl 10:S178-85.

22) Bellairs JA, Hasina R, Agrawal N. Tumor DNA: An emerging biomarker in head and neck cancer. Cancer Metastasis Rev 2017;36(3):515-23.

23) Hilkje FJ, Muyas F, Admard J, Kootz B, Nann D, Welz S, et al. Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy. Radiother Oncol 2020;151:182-9.

24) Verma T, Kumari S, Mishra S, Rastogi M, Tiwari V, Agarwal GR, et al. Circulating free DNA as a marker of response to chemoradiation in locally advanced head and neck squamous cell carcinoma. Indian J Pathol Microbiol 2020;63(4):521-6.

25) Mutschelknaus L, Azimzadeh O, Heider T, Winkler K, Vetter M, Kell R, et al. Radiation alters the cargo of exosomes released from squamous head and neck cancer cells to promote migration of recipient cells. Sci Rep 2017;7(1):12423.

26) Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92(3):205-16.

27) Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47.

28) Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122S-50.

29) Kishikawa T, Suzuki M, Takehito N, Fukusumi T, Michita T, Hanamoto A, et al. Response evaluation criteria in solid tumors (RECIST) and PET response criteria in solid tumors (PERCIST) for response evaluation of the neck after chemoradiotherapy in head and neck squamous cell carcinoma. Head Neck 2021;43(4):1184-93.

30) Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brzel DM, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020;18(7):873-98.
35) Koksel Y, Gencturk M, Spano A, Reynolds M, Roshan S, Cayci Z. Utility of Likert scale (Deauville criteria) in assessment of chemoradiotherapy response of primary oropharyngeal squamous cell cancer site. Clin Imaging 2019;55:89-94.
36) Aiken AH, Rath TJ, Anzai Y, Branstetter BF, Hoang JK, Wiggins RH, et al. ACR neck imaging reporting and data systems (NI-RADS): A white paper of the ACR NI-RADS committee. J Am Coll Radiol 2018;15(8):1097-108.
37) Zhong J, Sundersingh M, Dyker K, Currie S, Vaidyanathan S, Prestwich R, et al. Post-treatment FDG PET-CT in head and neck carcinoma: Comparative analysis of 4 qualitative interpretative criteria in a large patient cohort. Sci Rep 2020;10(1):4086.